Evidence map›Paper›PMID 42088571›Full record

ReviewFrontiers in pharmacology2026

Biomedical applications and perspectives of two-dimensional porphyrin-based MOFs.

Cheng Qi, Xuanxuan Luo, Huoying Pan, Weiqi Wang, Xiaohua Zheng

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Cheng QiThe People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Danyang, Jiangsu, China.
Xuanxuan LuoSchool of Pharmacy, Nantong University, Nantong, Jiangsu, China.
Huoying PanSchool of Pharmacy, Nantong University, Nantong, Jiangsu, China.
Weiqi WangSchool of Pharmacy, Nantong University, Nantong, Jiangsu, China.
Xiaohua ZhengSchool of Pharmacy, Nantong University, Nantong, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two-dimensional porphyrin-based metal-organic frameworks (2D Por-MOFs) have emerged as promising candidates in biomedical applications due to their ultrathin morphology, high surface area, tunable electronic properties, and excellent optical characteristics. This review systematically summarizes recent advances in their utilization for cancer therapy, antibacterial treatment, and biosensing. In oncology, 2D Por-MOFs serve as efficient photosensitizers for photodynamic therapy (PDT) by generating reactive oxygen species (ROS) to eradicate tumor cells, while also enabling synergistic therapeutic outcomes through integration with chemodynamic therapy (CDT), chemotherapy, immunotherapy, sonodynamic therapy (SDT), and novel mechanisms such as copper-dependent cell death. For antibacterial applications, these materials enhance ROS production via size engineering, single-atom modification, or nanozyme loading, effectively killing pathogens and promoting wound healing, as well as being incorporated into smart dressings to achieve combined hemostatic and antimicrobial functions. In biosensing, 2D Por-MOFs act as ideal platforms for photoelectrochemical signal transduction or fluorescent probes, facilitating the development of highly sensitive fiber-optic SPR, electrochemical, and fluorescence sensors capable of detecting disease biomarkers, pathogens, small-molecule metabolites, and ions with high sensitivity. Finally, the current challenges and future prospects for the clinical translation of 2D Por-MOFs are discussed.

Indexed as

antibacterial treatmentbiosensingcancer therapymetal-organic frameworksporphyrin

Identifiers

PMID42088571
PMCPMC13136281

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.